Neogen Corporation Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net
Neogen Corporation (NEOG) reported Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net of $2.96 million for the 3-month period ending 2023-08-31, per its 10-Q filed 2023-10-10.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet · last filed 2023-10-10
- Neogen Corporation derivative instruments not designated as hedging instruments, gain (loss), net for the quarter ending 2023-08-31 was $2.96M.
- Neogen Corporation derivative instruments not designated as hedging instruments, gain (loss), net for the quarter ending 2023-05-31 was -$2.59M.
- Neogen Corporation derivative instruments not designated as hedging instruments, gain (loss), net for the quarter ending 2023-02-28 was $2.98M.
- Neogen Corporation derivative instruments not designated as hedging instruments, gain (loss), net for the quarter ending 2022-11-30 was -$2.43M.
- Neogen Corporation derivative instruments not designated as hedging instruments, gain (loss), net for fiscal 2023 was -$2.04M.
| Period end | Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 3 month | Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 6 month | Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 9 month | Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 12 month |
|---|---|---|---|---|
| 2023-08-31 | $2.96M 10-Q · filed 2023-10-10 | $367.00K derived: sum of 2 quarters · filed 2023-10-10 | $3.35M derived: sum of 3 quarters · filed 2023-10-10 | $917.00K derived: sum of 4 quarters · filed 2023-10-10 |
| 2023-05-31 | -$2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-15 | $389.00K derived: sum of 2 quarters · filed 2023-08-15 | -$2.04M derived: sum of 3 quarters · filed 2023-08-15 | -$2.04M 10-K · filed 2023-08-15 |
| 2023-02-28 | $2.98M 10-Q · filed 2023-04-04 | $550.00K derived: sum of 2 quarters · filed 2023-04-04 | $550.00K 10-Q · filed 2023-04-04 | |
| 2022-11-30 | -$2.43M 10-Q · filed 2023-01-09 | -$2.43M 10-Q · filed 2023-01-09 | ||
| 2022-08-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2023-08-15 | |||
| 2022-02-28 | $0.00 10-Q · filed 2023-04-04 | $0.00 derived: sum of 2 quarters · filed 2023-04-04 | $0.00 10-Q · filed 2023-04-04 | |
| 2021-11-30 | $0.00 10-Q · filed 2023-01-09 | $0.00 10-Q · filed 2023-01-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |